Report: Imported Liposomal Doxorubicin Yields Similar Outcomes as Approved OC Formulation

Report: Imported Liposomal Doxorubicin Yields Similar Outcomes as Approved OC Formulation
A non-approved formulation of pegylated liposomal doxorubicin — called Lipodox — seems to lead to similar response rates and time to disease progression in ovarian cancer patients as the approved Doxil formulation, results from a single institution show. The findings suggest that treatment with Lipodox during a shortage of Doxil in 2012 did not result in different therapeutic outcomes for these patients. The study, "Comparing Outcomes in Patients with Recurrent or Refractory Ovarian Cancer Managed with 1 of 2 Versions of Pegylated Liposomal Doxorubicin at an Academic Medical Center," was published in the Journal of Hematology Oncology Pharmacy. Typically, ovarian cancer patients receive surgery and platinum-based chemotherapy as their first-line treatment. But most patients relapse and require additional therapies. Pegylated liposomal doxorubicin is a kind of chemotherapy that may be given as a second-line option to ovarian cancer patients, regardless of whether they first responded to or failed platinum-based chemotherapy. The treatment consists of tiny spheres containing the chemotherapeutic agent doxorubicin. The spheres, called liposomes, are made to last longer in circulation and to reach and accumulate in cancer sites mo
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *